Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations.

Blood neoplasia·2026

Same author

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Annals of hematology·2026

Same author

Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity.

Transplantation and cellular therapy·2026

Same author

Cancer epidemiology in the Kingdom of Saudi Arabia, 2024.

Hematology/oncology and stem cell therapy·2026

Same author

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

Bone marrow transplantation·2026

Same author

Progressive transformation of germinal centers: Bridging clinical and pathological insights for diagnostic precision.

Hematology/oncology and stem cell therapy·2026

Search research articles

Related Experiment Video

Updated: Feb 14, 2026

Culture of myeloid dendritic cells from bone marrow precursors

Culture of myeloid dendritic cells from bone marrow precursors

Published on: July 25, 2008

Azacitidine Use for Myeloid Neoplasms.

Riad El Fakih¹, Rami Komrokji², Marwan Shaheen¹

¹King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Clinical Lymphoma, Myeloma & Leukemia

|February 27, 2018

Summary

Azacitidine, a hypomethylating agent, effectively treats myeloid neoplasms by inhibiting DNA methyltransferases. It is well-tolerated and suitable for outpatient treatment, making it a valuable therapeutic option.

Keywords:

AML HMA Hypomethylating agent Myelosysplastic syndrome

More Related Videos

Identification and Isolation of Oligopotent and Lineage-committed Myeloid Progenitors from Mouse Bone Marrow

Identification and Isolation of Oligopotent and Lineage-committed Myeloid Progenitors from Mouse Bone Marrow

Published on: July 29, 2018

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Feb 14, 2026

Culture of myeloid dendritic cells from bone marrow precursors

Culture of myeloid dendritic cells from bone marrow precursors

Published on: July 25, 2008

Identification and Isolation of Oligopotent and Lineage-committed Myeloid Progenitors from Mouse Bone Marrow

Identification and Isolation of Oligopotent and Lineage-committed Myeloid Progenitors from Mouse Bone Marrow

Published on: July 29, 2018

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Area of Science:

Oncology
Pharmacology
Molecular Biology

Background:

Azacitidine and decitabine are key hypomethylating agents used in treating myeloid neoplasms.
These agents inhibit DNA methyltransferases, leading to demethylation of aberrant gene promoters in myeloid cancer pathogenesis.
Azacitidine, approved in 2004 for myelodysplastic syndrome, has seen expanded use in other myeloid neoplasms.

Purpose of the Study:

To review the current literature on azacitidine's application in myeloid neoplasms.
To highlight the established efficacy and safety profile of azacitidine.
To provide insights into ongoing clinical trials involving azacitidine.

Main Methods:

Comprehensive literature review of published studies on azacitidine in myeloid neoplasms.
Analysis of clinical trial data and patient outcomes.
Summary of pharmacological mechanisms and tolerability data.

Main Results:

Azacitidine is metabolized intracellularly to decitabine, sharing a similar mechanism of action.
Demonstrated efficacy in various myeloid neoplasms, leading to significant clinical use.
Favorable safety profile allows for safe administration in outpatient settings.

Conclusions:

Azacitidine is a well-tolerated and effective treatment for myeloid neoplasms.
Its outpatient administration enhances patient convenience and physician preference.
Further research through ongoing trials will continue to define its role in hematologic malignancies.